
Chugai Pharmaceutical Co. Ltd.
CHGCY | OTC
$20.94
-$0.52 (-2.42%)
Sep 24, 2026, 11:00 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.34T | 1.29T | 1.26T | 1.21T | 1.2T | 1.22T | 1.17T | 1.14T | 1.08T | 1.04T | 1.11T | 1.28T | 1.24T | 1.21T | 1.17T | 1.05T | 1.11T | 1.1T | 999.76B | 887.92B | 809.06B | 776.34B |
Cost of Revenue | 384.21B | 368.66B | 363.69B | 370.43B | 354.41B | 354.28B | 339.41B | 337.17B | 331.21B | 334.93B | 413.31B | 534.16B | 525B | 513.16B | 476.25B | 373.43B | 408.53B | 396.77B | 337.68B | 299.86B | 265.02B | 267.53B |
Gross Profit | 958.6B | 922.57B | 894.25B | 843.28B | 841.81B | 867.84B | 831.2B | 805.18B | 753.36B | 701.15B | 698.06B | 741.9B | 718.44B | 698.48B | 691.78B | 678.37B | 705.25B | 702.81B | 662.08B | 588.06B | 544.04B | 508.81B |
Operating Income | 634.29B | 613.99B | 590.19B | 581.41B | 562.92B | 582.38B | 545.06B | 536.27B | 482.49B | 423.93B | 425.96B | 463.7B | 453.88B | 455.17B | 450.44B | 443.27B | 470.79B | 467.52B | 433.74B | 364.59B | 327.8B | 297.93B |
Interest Income | n/a | n/a | n/a | n/a | n/a | 480M | 495M | 495M | 495M | 15M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 655.2B | 622.18B | 597.81B | 553.41B | 556.17B | 578.97B | 543.03B | 540.22B | 488.86B | 444.05B | 443.82B | 470.35B | 457.9B | 444.62B | 531.17B | 520.39B | 545.05B | 541.35B | 419.39B | 354B | 319.88B | 291.21B |
Net Income | 471.37B | 452.2B | 434.01B | 397.2B | 395.49B | 410.19B | 387.36B | 386.96B | 355.04B | 326.37B | 325.47B | 336.75B | 326.97B | 316.15B | 374.43B | 370.79B | 389.01B | 387.36B | 303B | 256.46B | 230.58B | 210.61B |
Selling & General & Admin | 133.06B | 120.03B | 116.46B | 74.45B | 95.15B | 104.45B | 104.79B | 97.94B | 99.4B | 104.35B | 102.28B | 105.3B | 100.55B | 91.22B | 93.76B | 97.3B | 98.12B | 99.36B | 96.39B | 94.39B | 92.09B | 89.95B |
Research & Development | 190.65B | 188.56B | 187.6B | 187.42B | 183.74B | 181.01B | 181.35B | 170.98B | 171.48B | 172.87B | 169.82B | 172.89B | 164.01B | 152.09B | 147.58B | 137.8B | 136.34B | 135.93B | 131.95B | 129.08B | 124.15B | 120.93B |
Other Expenses | 600M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 324.31B | 308.58B | 304.06B | 261.87B | 278.88B | 285.46B | 286.15B | 268.92B | 270.87B | 277.21B | 272.1B | 278.19B | 264.56B | 243.31B | 241.34B | 235.1B | 234.46B | 235.3B | 228.34B | 223.47B | 216.24B | 210.88B |
Interest Expense | 972M | 972M | 972M | 58M | n/a | n/a | n/a | 8M | 15M | 24M | 26M | 34M | 42M | 48M | 60M | 56M | 53M | 50M | 48M | 542M | 549M | 548M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 708.51B | 677.24B | 667.75B | 632.31B | 633.29B | 639.74B | 625.56B | 606.08B | 602.08B | 612.14B | 685.4B | 812.35B | 789.56B | 756.46B | 717.59B | 608.53B | 642.99B | 632.06B | 566.02B | 523.33B | 481.26B | 478.41B |
Income Tax Expense | 183.83B | 169.98B | 163.79B | 156.25B | 160.73B | 168.83B | 155.72B | 153.25B | 133.82B | 117.68B | 118.35B | 133.6B | 130.93B | 128.47B | 156.74B | 149.6B | 156.04B | 153.99B | 116.39B | 97.53B | 89.3B | 80.6B |
Shares Outstanding (Basic) | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B |
Shares Outstanding (Diluted) | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B |
EPS (Basic) | 286.43 | 274.78 | 263.74 | 241.35 | 240.31 | 249.25 | 235.38 | 235.17 | 215.78 | 198.37 | 197.83 | 204.70 | 198.76 | 192.19 | 227.65 | 225.46 | 236.56 | 235.58 | 184.28 | 156.02 | 140.29 | 128.16 |
EPS (Diluted) | 286.43 | 274.78 | 263.73 | 241.34 | 240.29 | 249.22 | 235.35 | 235.14 | 215.75 | 198.34 | 197.80 | 204.65 | 198.72 | 192.15 | 227.57 | 225.37 | 236.44 | 235.44 | 184.17 | 155.94 | 140.21 | 128.07 |
EBITDA | 688.3B | 664.14B | 631.37B | 575.67B | 558.97B | 581.77B | 545.83B | 543.02B | 491.57B | 446.77B | 446.65B | 472.18B | 459.95B | 446.57B | 532.93B | 523.65B | 548.2B | 545.4B | 423.44B | 356.74B | 322.63B | 293.06B |
EBIT | 647.77B | 623.2B | 598.83B | 553.47B | 556.17B | 578.97B | 543.03B | 540.22B | 488.87B | 444.07B | 443.85B | 470.38B | 457.95B | 444.67B | 531.23B | 520.45B | 545.1B | 541.4B | 419.43B | 354.54B | 320.43B | 291.76B |
Depreciation & Amortization | 40.54B | 40.94B | 32.54B | 22.2B | 2.8B | 2.8B | 2.8B | 2.8B | 2.7B | 2.7B | 2.8B | 1.8B | 2B | 1.9B | 1.7B | 3.2B | 3.1B | 4B | 4B | 2.2B | 2.2B | 1.3B |
Add to Watchlist
Select watchlists to add or remove CHGCY